Distribution of cyclooxygenase products with cyclooxygenase inhibition in isolated dog lung

• Published in: Journal of applied physiology (1985) Vol. 61; no. 3; p. 988
• Main Authors: Littner, M R, Kazmi, G M, Lott, F D
• Format: Journal Article
• Language: English
• Published: United States 01.09.1986
• Subjects: 6-Ketoprostaglandin F1 alpha - metabolism; Animals; Arachidonic Acid; Arachidonic Acids - metabolism; Arachidonic Acids - pharmacology; Cyclooxygenase Inhibitors; Dinoprost; Dinoprostone; Dogs; In Vitro Techniques; Indomethacin - pharmacology; Lung - drug effects; Lung - metabolism; Perfusion; Prostaglandin-Endoperoxide Synthases - metabolism; Prostaglandins E - metabolism; Prostaglandins F - metabolism; Thromboxane B2 - metabolism
• ISSN: 8750-7587
• DOI: 10.1152/jappl.1986.61.3.988

Arachidonic acid metabolism can lead to synthesis of cyclooxygenase products in the lung as indicated by measurement of such products in the perfusate of isolated lungs perfused with a salt solution. However, a reduction in levels of cyclooxygenase products in the perfusate may not accurately reflect the inhibition of levels of such products as measured in lung parenchyma. We infused sodium arachidonate into the pulmonary circulation of isolated dog lungs perfused with a salt solution and measured parenchymal, as well as perfusate, levels of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha), prostaglandin F2 alpha (PGF2 alpha), prostaglandin E2 (PGE2), and thromboxane B2 (TxB2). These studies were repeated with indomethacin (a cyclooxygenase enzyme inhibitor) in the perfusate. We found that indomethacin leads to a marked reduction in perfusate levels of PGF2 alpha, PGE2, 6-keto-PGF1 alpha, and TxB2, as well as a marked reduction in parenchymal levels of 6-keto-PGF1 alpha and TxB2 when parenchymal levels of PGF2 alpha and PGE2 are not reduced. We conclude that, with some cyclooxygenase products, a reduction in levels of these products in the perfusate of isolated lungs may not indicate inhibition of levels of these products in the lung parenchyma and that a reduction in one parenchymal product may not predict the reduction of other parenchymal products. It can be speculated that some of the physiological actions of indomethacin in isolated lungs may result from incomplete or selective inhibition of synthesis of pulmonary cyclooxygenase products.